- Trials with a EudraCT protocol (3,493)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (12)
3,493 result(s) found for: Platelet.
Displaying page 1 of 175.
EudraCT Number: 2013-000965-34 | Sponsor Protocol Number: E5501-G000-310 | Start Date*: 2014-05-27 | ||||||||||||||||||||||||||
Sponsor Name:Eisai Limited | ||||||||||||||||||||||||||||
Full Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia ... | ||||||||||||||||||||||||||||
Medical condition: Thrombocytopenia in Patients with Chronic Liver Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) IT (Completed) GB (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005803-42 | Sponsor Protocol Number: 2012-12 | Start Date*: 2013-03-21 |
Sponsor Name:Universitetssjukhuset Örebro | ||
Full Title: Evaluation of platelet function following cessation of ticagrelor - a study in patients with acute coronary syndrome and PCI with coronary stent | ||
Medical condition: Return of platelet function following cessation of oral anti-platelet treatment with ticagrelor | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000665-20 | Sponsor Protocol Number: 2012-02 | Start Date*: 2012-04-05 |
Sponsor Name:Universitetssjukhuset Örebro | ||
Full Title: Evaluation of platelet function following cessation of ticagrelor - a study in patients with acute coronary syndrome and PCI with coronary stent | ||
Medical condition: Return of platelet function following cessation of oral anti-platelet treatment with ticagrelor. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000934-36 | Sponsor Protocol Number: E5501-G000-311 | Start Date*: 2014-06-16 | ||||||||||||||||||||||||||
Sponsor Name:Eisai Limited | ||||||||||||||||||||||||||||
Full Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia ... | ||||||||||||||||||||||||||||
Medical condition: Thrombocytopenia in Patients with Chronic Liver Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) IT (Completed) ES (Completed) CZ (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000830-12 | Sponsor Protocol Number: E5501-G000-302 | Start Date*: 2012-08-28 | ||||||||||||||||||||||||||
Sponsor Name:Eisai Limited | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care... | ||||||||||||||||||||||||||||
Medical condition: Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) SK (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) GR (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000831-10 | Sponsor Protocol Number: E5501-G000-305 | Start Date*: 2012-07-16 | ||||||||||||||||||||||||||
Sponsor Name:Eisai Limited | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, i... | ||||||||||||||||||||||||||||
Medical condition: Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004772-19 | Sponsor Protocol Number: 04122019 | Start Date*: 2020-04-08 |
Sponsor Name:Steno Diabetes Center Copenhagen | ||
Full Title: Platelet aggregation and aspirin low response in type one diabetes and the association with vascular damage and diabetic nephropathy | ||
Medical condition: Prevention of cardiovascular disease in persons with type 1 diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005068-16 | Sponsor Protocol Number: 221181 | Start Date*: 2018-02-14 | |||||||||||
Sponsor Name:University Hospital of Aarhus | |||||||||||||
Full Title: Measurement of Acetylsalicylic acid Concentration and Effect - MACE | |||||||||||||
Medical condition: Healthy volunteers (Prophylaxis of arterial thrombosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006143-40 | Sponsor Protocol Number: IP-001 | Start Date*: 2009-07-30 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik Innere Medizin I | ||
Full Title: Assessment of platelet function in patients with chronic autoimmune thrombocytopenic purpura (cAITP) treated with the thrombopoietin receptor (MPL) agonist Eltrombopag | ||
Medical condition: patients suffering from chronic autoimmune thrombocytopenia the platelet function/activation will be investigated the rise of reticulated platelets and variation of platelet antibodies will be inve... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003232-24 | Sponsor Protocol Number: AVA-PED-301 | Start Date*: 2020-12-03 | ||||||||||||||||||||||||||
Sponsor Name:Dova Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment... | ||||||||||||||||||||||||||||
Medical condition: Thrombocytopenia in paediatric subjects with immune thrombocytopenia for ≥6 months duration who have had an insufficient response to a previous treatment | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) HU (Completed) DE (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004032-21 | Sponsor Protocol Number: ARGX-113-2004 | Start Date*: 2021-05-07 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immu... | |||||||||||||
Medical condition: Primary immune thrombocytopenia (ITP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) PT (Completed) DE (Completed) BG (Completed) NO (Completed) DK (Completed) GR (Completed) IT (Completed) FR (Completed) RO (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001410-16 | Sponsor Protocol Number: 25032013 | Start Date*: 2013-07-01 |
Sponsor Name:Netherlands Heart Foundation | ||
Full Title: Effects of low-dose aspirin taken at bedtime vs. on awakening on circadian rhythm of platelet function in healthy subjects | ||
Medical condition: platelet reactivity | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000017-20 | Sponsor Protocol Number: ASS-Metamizol-DDI | Start Date*: 2018-07-17 |
Sponsor Name:Universitäts-Herzzentrum Freiburg • Bad Krozingen | ||
Full Title: Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole) | ||
Medical condition: Antithrombotic therapy after surgical replacement of stenotic heart valve by a bioprosthesis or mitral valve repair | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020219-35 | Sponsor Protocol Number: | Start Date*: 2011-07-18 |
Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust | ||
Full Title: Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI | ||
Medical condition: Cardiovascular disease - Acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005454-30 | Sponsor Protocol Number: C-935788-049 | Start Date*: 2014-11-28 | |||||||||||
Sponsor Name:Rigel Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura | |||||||||||||
Medical condition: Persistent/Chronic Immune Thrombocytopenic Purpura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) HU (Completed) CZ (Completed) AT (Completed) NL (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000968-30 | Sponsor Protocol Number: RC31/19/0509 | Start Date*: 2021-04-13 | |||||||||||
Sponsor Name:CHU Toulouse | |||||||||||||
Full Title: ASPirin in Immune thRombocytopenia patients with cardiovascular disEase | |||||||||||||
Medical condition: Immune thrombocytopenia with cardiovascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000499-89 | Sponsor Protocol Number: DK0100 | Start Date*: 2015-11-09 |
Sponsor Name:Royal College Of Surgeons Ireland | ||
Full Title: To measure the effects of Aspirin loading dose of 300mgs in healthy controls using AA LTA and the Dynamic Platelet Function Assay (DPFA). | ||
Medical condition: Cardiovascular disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001620-31 | Sponsor Protocol Number: CZB/4/622 | Start Date*: 2009-09-14 |
Sponsor Name:NHS Highland | ||
Full Title: Glutathione Status in Platelets From Patients With Type 2 Diabetes: Therapeutic Potential of N-acetylcysteine to Help Prevent Platelet Hyperaggregability | ||
Medical condition: Platelet Aggregation in type 2 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002896-32 | Sponsor Protocol Number: D5136C00001 | Start Date*: 2013-01-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A multicenter, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic, safety and tolerability study in patients aged 12 to <18 years of age with a central venous catheter to support pr... | |||||||||||||
Medical condition: Thrombosis, thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003653-17 | Sponsor Protocol Number: 992 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic... | |||||||||||||
Medical condition: Chronic primary immune thrombocytopenia (ITP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
